Study identifier:D1693C00001
ClinicalTrials.gov identifier:NCT01730534
EudraCT identifier:N/A
CTIS identifier:N/A
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes
Diabetes Mellitus, Non-Insulin-Dependent
Phase 3
No
Dapagliflozin 10 mg, Placebo tablet
All
17190
Interventional
40 Years - 130 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2019 by AstraZeneca
AstraZeneca
Bristol-Myers Squibb, The TIMI Study Group, Hadassah Medical Organization
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
Location
Location
Buenos Aires, Argentina, C1425AGC
Location
Geelong, Australia, 3220
Location
Sofia, Bulgaria, 1223
Location
Botevgrad, Bulgaria, 2140
Location
Dimitrovgrad, Bulgaria, 6400
Location
Dupnitsa, Bulgaria, 2600
Location
Gotse Delchev, Bulgaria, 2900
Location
Kozloduy, Bulgaria, 3320
Arms | Assigned Interventions |
---|---|
Experimental: Dapagliflozin Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors | Drug: Dapagliflozin 10 mg Oral dose (od) |
Placebo Comparator: Placebo Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors | Drug: Placebo tablet Oral dose (od) |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.